Publications by authors named "Lewis F Nasr"

Background: The prognosis of multiple myeloma involving the central nervous system (CNS-MM) is poor. We report outcomes of CNS-MM treated with CNS-directed radiation therapy (RT).

Methods: We retrospectively reviewed patients with CNS-MM treated with CNS-directed RT from 2015 to 2024.

View Article and Find Full Text PDF

Background: Diffuse large B-cell lymphoma (DLBCL) involving the gastrointestinal (GI) organs is rare, and real-world outcomes after combined modality therapy (CMT) with systemic therapy (ST) and radiotherapy (RT) are not well-characterized, particularly in the contemporary era. We characterized outcomes in a large cohort of GI-DLBCL patients treated with ST alone or CMT.

Methods: Patients with GI-DLBCL treated at a single institution were retrospectively reviewed.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers looked at how bridging radiation therapy (bRT) affects people getting CAR T-cell therapy for a type of cancer called large B-cell lymphoma.
  • They found that bRT can be safely given, but it didn't seem to help or hurt the patients' outcomes in terms of blood cell counts or how well they responded to the CAR T-cell treatment.
  • The study suggests that while bRT is safe, careful planning is needed to manage any risks after the treatment.
View Article and Find Full Text PDF

Background: Undifferentiated pleomorphic sarcomas (UPSs) are amongst the most common subtypes of soft-tissue sarcomas. Few real-world data on the use of immune checkpoint blockade (ICB) in UPS patients and other high-grade pleomorphic STS patients are available.

Purpose: The purpose of our study is to describe the efficacy and toxicity of ICB in patients with advanced UPSs and other high-grade pleomorphic sarcomas treated at our institution.

View Article and Find Full Text PDF
Article Synopsis
  • * The study found that 11% of patients who relapsed after InO developed mutations in the CD22 gene, which allowed cancer cells to evade treatment, often through losing or altering the CD22 protein's structure.
  • * Additional mutations were also seen in genes related to DNA damage response, raising concerns about how cancer cells adapt post-treatment, emphasizing the need for understanding these mechanisms to improve future therapies, especially before procedures like stem cell transplantation.
View Article and Find Full Text PDF

Purpose: Azacitidine plus venetoclax is a standard of care for patients with newly diagnosed AML who are unfit for intensive chemotherapy. However, mutations are a common mechanism of resistance to this regimen. The addition of gilteritinib, an oral FLT3 inhibitor, to azacitidine and venetoclax may improve outcomes in patients with -mutated AML.

View Article and Find Full Text PDF

Background: The combination of low-intensity chemotherapy and inotuzumab ozogamicin (INO), with sequential blinatumomab, is highly effective in older adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) and in relapsed or refractory B-cell ALL. Earlier, "dose-dense" administration of blinatumomab could lead to earlier and deeper measurable residual disease (MRD) responses and better outcomes.

Patients And Methods: We performed a retrospective analysis of the safety and efficacy of a dose-dense regimen of mini-hyper-CVD (mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone alternating with mini-methotrexate and cytarabine), INO, and blinatumomab in patients with B-cell ALL.

View Article and Find Full Text PDF
Article Synopsis
  • Inotuzumab ozogamicin (InO) is a targeted therapy for B-cell acute lymphoblastic leukemia that delivers a cytotoxic drug to cells expressing the CD22 antigen.
  • A study on patients treated with InO revealed that approximately 11% exhibited genomic mutations contributing to treatment resistance, with various escape mechanisms like protein truncation and destabilization.
  • The findings highlight the role of DNA damage repair processes in promoting CD22 mutations and suggest that understanding these genetic changes can help improve treatment strategies for overcoming resistance to therapy.
View Article and Find Full Text PDF